Between 1940 and 1991, the laboratory in Yaba had been the steady heart of the nation’s health, producing doses for yellow fever and smallpox that were shared across the border with neighbors. When the machinery finally went still due to a lack of maintenance and funds, the country began a long period of total dependence, importing every routine vial from overseas through international intermediaries. The restart of operations in 2025, under a partnership with May & Baker Nigeria Plc, does more than fill shelves; it restores a lost capability.
The current output focuses on the most intimate threats to the population: malaria and HPV. By producing these vaccines on home soil, the government bypasses the heavy markups and logistical delays of the global market. For a family in a distant province, this translates to a vaccine that is present when needed, funded by the state rather than out-of-pocket sacrifices.
This industrial revival is paired with a broad human effort. Beyond the factory walls, 120,000 health workers are being trained to bring these doses to the people, while 17,000 local clinics are being rebuilt to house them. The goal is a system where the medicine is as reliable as the people administering it.
As the technician watches the conveyor move, there is no fanfare, only the steady, mechanical proof of a promise kept. The ambition to cover 83 million citizens under the National Health Insurance Scheme by 2030 rests on these small, clear vials. In the heat of Lagos, the cool glass of a locally made vaccine represents a nation finally looking after its own.